Fagron Compounding Services recalled 5,140 bags of norepinephrine Bitartrate injection due to lack of sterility assurance. A blue Break-Off-Part could detach from the administration port. The recall covers nationwide distribution in the U.S. Consumers should stop use and contact providers for guidance.
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Consumers and healthcare providers should stop using this product immediately. Contact Fagron Compounding Services or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Norepinephrine Bitartrate injections are used as vasopressors in critical care to raise blood pressure in hypotensive patients. They are typically prepared in hospital pharmacies or compounding centers.
A blue Break-Off-Part could detach from the administration port, raising sterility concerns and potential contamination risk.
This recall is not part of a broader industry pattern beyond sterility assurance issues in compounded IV solutions.
Immediate discontinuation is required for affected bags. Hospitals and patients may experience delays in critical vasopressor therapy while replacements are sourced.
Recall details are on FDA enforcement page and packaging labels.
Refunds/replacements typically managed through hospital purchasing channels; no public timeline specified.
Document lot numbers, expiration dates, and correspondences with the manufacturer and FDA.
Product: Norepinephrine Bitartrate, 32 mg per 250 mL 0.9% Sodium Chloride Injection USP. Company: Fagron Compounding Services. Address: 8710 34th St. N. Wichita, KS 67226. NDC: 71266-5027-02. Lot numbers and expirations include: C274-000050004 Exp. 4/24/2026; C274-000050295 Exp. 5/8/2026; C274-000050773 Exp. 6/4/2026; C274-000051219 Exp. 6/21/2026; C274-000051318 Exp. 6/27/2026; C274-000051602 Exp. 7/12/2026. Quantity: 5140 bags. Distribution: Nationwide in the USA. Recall date: 2026-03-20.
No injuries or incidents have been reported.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Fagron Compounding Services recalled 34,260 bags of Vancomycin HCI Injection across the United States. The recall cites lack of sterility assurance and a blue Break-Off-Part that could detach from the administration port. Healthcare providers and patients should stop using the product immediately and follow manufacturer guidance.
Fagron Compounding Services is recalling 11,680 bags of Vancomycin HCl 1 g in 250 mL 0.9% Sodium Chloride Injection. The recall is nationwide in the United States. The blue break-off part could detach from the administration port, raising sterility concerns. Stop using immediately and contact the provider for guidance.
Fagron Compounding Services recalled 2,980 syringes of a topical ophthalmic solution on November 20, 2025. The recall stems from an incorrect product formulation that could pose health risks. Consumers should stop using the product immediately and contact their healthcare provider for guidance.
Fagron Compounding Services recalls 109,320 sterile single-dose bevacizumab syringes nationwide due to lack of assurance of sterility. Healthcare providers and patients should stop using the product immediately. Contact Fagron Compounding Services or a healthcare provider for guidance. The recall was issued on 2025-08-29 and remains active as of 2025-09-24.